Sivarama Kotikalapudi, MD
Internal Medicine · Hattiesburg, MSNPI 1124069521
Payments from drug & device makers
Across 161 payments — averaging $19.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$912
- GSK$446
- Electromed, Inc.$192
- AbbVie$150
- Pfizer$141
- Bayer$118
- plus $1K from 23 others
What the payments were for
- Food & beverage$3,11199%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 41 | $912 |
| GSK | 23 | $446 |
| Electromed, Inc. | 12 | $192 |
| AbbVie | 17 | $150 |
| Pfizer | 8 | $141 |
| Bayer | 6 | $118 |
| Novo Nordisk | 6 | $117 |
| Philips North America LLC | 5 | $111 |
| Merck | 4 | $93 |
| Verona Pharma, Inc. | 4 | $90 |
| Global Blood Therapeutics, Inc. | 4 | $85 |
| Boehringer Ingelheim | 1 | $76 |
| Novartis | 4 | $72 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $72 |
| Abbott | 3 | $69 |
| Amgen | 3 | $60 |
| Shield Therapeutics Inc | 3 | $52 |
| Boston Scientific | 2 | $40 |
| Dexcom, Inc. | 1 | $31 |
| Johnson & Johnson | 2 | $31 |
| Kyowa Kirin, Inc. | 2 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $28 |
| Insulet Corporation | 1 | $24 |
| Exact Sciences | 1 | $23 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $21 |
| Melinta Therapeutics, LLC | 1 | $19 |
| Seqirus USA Inc | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
How this compares
$3,144 in reported general payments places this provider in the 80th percentile of 846 internal medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 112 | $133,666 |
| JardianceEmpagliflozin | 136 | $104,005 |
| OzempicSemaglutide | 75 | $95,118 |
| TrulicityDulaglutide | 87 | $93,465 |
| FarxigaDapagliflozin Propanediol | 115 | $84,936 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 74 | $63,082 |
| EliquisApixaban | 94 | $60,964 |
| XifaxanRifaximin | 12 | $44,701 |
| Tresiba Flextouch U-200Insulin Degludec | 45 | $38,369 |
| VraylarCariprazine Hcl | 23 | $35,333 |
| LinzessLinaclotide | 52 | $34,569 |
| EntrestoSacubitril/Valsartan | 29 | $21,033 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 47 | $19,160 |
| JanuviaSitagliptin Phosphate | 26 | $18,869 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $15,751 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Bevespi Aerosphere, Symbicort, Airsupra | $912 | $182,917288 claims |
| Boehringer IngelheimJardiance | $76 | $104,005136 claims |
| Novo NordiskOzempic | $117 | $95,11875 claims |
| AbbVieVraylar, Linzess | $150 | $69,90175 claims |
| PfizerEliquis | $141 | $60,96494 claims |
| MerckJanuvia, Dulera | $93 | $23,60239 claims |
| NovartisEntresto | $72 | $21,03329 claims |
| GSKTrelegy Ellipta | $446 | $15,75119 claims |
| Johnson & JohnsonXarelto | $31 | $10,40018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 846 internal medicine providers in Mississippi.
Other internal medicine in Hattiesburg
- Arnold JacksonHattiesburg$121K
- Alexey FominHattiesburg$13K
- Quenyatta Echols-WilliamsHattiesburg$8K
- Charles HernandezHattiesburg$7K
- James HallBrookhaven$4.8M
- Bob HutchinsJackson$4.6M
- Sidney GortonBelzoni$571K
- David PendleyGulfport$336K
- Sarah KerutJackson$319K
- Gabriel HernandezJackson$196K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.